SC Filed 2019-11-22 Event — SEC 0001104659-19-066346 →

Sofinnova Venture Partners IX, L.P. → NextCure, Inc. NXTC

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

3 transactions

3 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

9 filings by this filer

8 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 2.96

220,966 shares short · +3.6% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-10-27	ADAR1 Capital Management, LLC	10%+ owner	Buy	3,553	$5.10	$18K
2026-10-26	ADAR1 Capital Management, LLC	10%+ owner	Buy	1,672	$5.03	$8K
2026-10-23	ADAR1 Capital Management, LLC	10%+ owner	Buy	5,626	$4.83	$27K

Other 13D/G Filings on NextCure, Inc.

Filed	Form	Filer	Stake	Shares
2026-10-20	SCHEDULE 13G	JP Sailing Capital Ltd	—	—	view →
2026-08-14	SCHEDULE 13G	ADAR1 Capital Management, LLC	—	—	view →

Other Filings by Sofinnova Venture Partners IX, L.P.

Filed	Form	Issuer	Stake	Shares
2024-02-20	SC	Galera Therapeutics, Inc. GRTX	—	—	view →
2021-03-04	SC	Entasis Therapeutics Holdings Inc.	—	—	view →
2020-06-05	SC	Iterum Therapeutics plc ITRMF	—	—	view →
2020-04-27	SC	Merus N.V.	—	—	view →
2020-01-27	SC	Iterum Therapeutics plc ITRMF	—	—	view →
2019-02-12	SC	aTYR PHARMA INC ATYR	—	—	view →
2019-02-12	SC	Ascendis Pharma A/S ASND	—	—	view →
2019-01-11	SC	Ascendis Pharma A/S ASND	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →